Setrusumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Apr 28, 2022 → Jul 7, 2022
NCT ID
NCT05312697About Setrusumab
Setrusumab is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is terminated. This product is registered under clinical trial identifier NCT05312697. Target conditions include Osteogenesis Imperfecta.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06636071 | Phase 3 | Active |
| NCT05312697 | Phase 2 | Terminated |
| NCT05125809 | Phase 2/3 | Active |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 85 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 3 | 77 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 76 |
| Romosozumab | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 76 |
| Fresolimumab | Sanofi | Phase 1 | 32 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 32 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 60 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |